| Literature DB >> 28232409 |
Helen E Jo1,2, Ian Glaspole3,4, Christopher Grainge5, Nicole Goh3,6, Peter M A Hopkins7, Yuben Moodley8, Paul N Reynolds9, Sally Chapman9, E Haydn Walters10, Christopher Zappala11, Heather Allan12, Gregory J Keir13, Andrew Hayen14, Wendy A Cooper14, Annabelle M Mahar15, Samantha Ellis15, Sacha Macansh12, Tamera J Corte1,2.
Abstract
7The prevalence of idiopathic pulmonary fibrosis (IPF), a fatal and progressive lung disease, is estimated at 1.25-63 out of 100 000, making large population studies difficult. Recently, the need for large longitudinal registries to study IPF has been recognised.The Australian IPF Registry (AIPFR) is a national registry collating comprehensive longitudinal data of IPF patients across Australia. We explored the characteristics of this IPF cohort and the effect of demographic and physiological parameters and specific management on mortality.Participants in the AIPFR (n=647, mean age 70.9±8.5 years, 67.7% male, median follow up 2 years, range 6 months-4.5 years) displayed a wide range of age, disease severity and co-morbidities that is not present in clinical trial cohorts. The cumulative mortality rate in year one, two, three and four was 5%, 24%, 37% and 44% respectively. Baseline lung function (forced vital capacity, diffusing capacity of the lung for carbon monoxide, composite physiological index) and GAP (gender, age, physiology) stage (hazard ratio 4.64, 95% CI 3.33-6.47, p<0.001) were strong predictors of mortality. Patients receiving anti-fibrotic medications had better survival (hazard ratio 0.56, 95% CI 0.34-0.92, p=0.022) than those not on anti-fibrotic medications, independent of underlying disease severity.The AIPFR provides important insights into the understanding of the natural history and clinical management of IPF.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28232409 DOI: 10.1183/13993003.01592-2016
Source DB: PubMed Journal: Eur Respir J ISSN: 0903-1936 Impact factor: 16.671